Viking Therapeutics has strong R&D, dual-track obesity drugs, and solid cash runway. Click here to read an analysis of VKTX ...

Viking Therapeutics shares fall in Wednesday's after-hours session after the company reported financial results for the ...

Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its ...

Every investor in Viking Therapeutics, Inc. (NASDAQ:VKTX) should be aware of the most powerful shareholder groups. We can see that institutions own the lion's share in the company with 70% ownership.

Viking Therapeutics reported a solid financial standing with $808 million in cash, cash equivalents, and short-term investments. This strong cash position provides a substantial financial runway to ...

Brian Lian, President and CEO, reported that "the Viking team continued to focus on execution of our core clinical strategy," emphasizing advancement of both oral and subcutaneous VK2735 programs. "We ...

Viking Therapeutics ( ($VKTX) ) has risen by 7.76%. Read on to learn why. Viking Therapeutics has seen a notable 7.76% ...

Loss per share was $(0.58), falling short of analyst expectations by $(0.13), or 29.1% (GAAP, Q2 2025). - Research and development expenses rose to $60.2 million in Q2 2025, up from $23.8 million in ...

In addition to Stifel Nicolaus, Viking Therapeutics also received a Buy from William Blair’s Andy Hsieh in a report issued today. However, yesterday, Citi maintained a Hold rating on Viking ...

We came across a bullish thesis on Viking Therapeutics, Inc. on r/wallstreetbets subreddit by Dritzz-9966. In this article, ...

Investing.com -- Viking Therapeutics, Inc. (NASDAQ: VKTX) reported a wider-than-expected second quarter loss on Wednesday, sending shares down 4.2% as investors reacted to the earnings miss despite ...

CEO Emma Walmsley’s 40-bln-pound 2031 sales target looks fanciful after another disappointing drug trial. A healthy balance ...